Bitterroot Bio Completes Enrollment in Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

Palo Alto, California, Needham, Massachusetts and Melbourne, Australia – October 29, 2024 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced the completion of enrollment in its Phase 1 study evaluating BRB-002 in healthy volunteers. This randomized, placebo-controlled, double-blinded, single ascending dose study is evaluating the safety, tolerability […]